Biocept (BIOCQ) 10-Q2016 Q1 Quarterly report

Filed: 13 May 16, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	Coll freshman Avg

New words: absence, accelerate, acceleration, advisory, agreed, androgen, approach, arising, arithmetic, Aspire, award, bearing, began, call, callable, category, clarifying, classification, commitment, committed, compute, concurrently, contingent, counterparty, CPT, criteria, dedesignation, deemed, deficit, diagnosed, distinguishing, dividend, Drug, dual, earliest, economic, eliminated, external, firm, Food, forfeited, gain, hedge, hedging, inconsistent, indirect, inhibitor, instrument, large, lender, lesser, lowest, menu, metastatic, modified, network, noncancelable, notice, organization, payor, pending, placement, preceding, prohibit, put, recapitalization, recoverability, refusal, rental, reorganization, revised, ROTH, satisfaction, separately, signatory, simplifying, split, submitted, Tagrisso, transaction, transactional, transition, tyrosine, unconditional, variable, variety, vendor, Wainwright

Removed: added, aforementioned, alleged, amortization, annually, automatically, behalf, borrowed, borrowing, canceled, cancelled, capitalization, ceased, CEE, certificate, codon, Commissioner, component, contemplated, converted, covered, covering, deduction, director, disbursed, divided, employee, employment, enumeration, Erbitux, expressed, federal, fewer, found, hearing, incorporating, incorporation, invested, IPO, issuable, iv, ix, Labor, launched, line, linked, managed, NASDAQ, noted, OncoCEE, par, partial, percent, policy, premium, President, proceeding, proportion, receipt, reflected, refund, registered, repaid, representative, request, respond, resulted, revolving, Rule, salary, seeking, serve, settled, settlement, source, state, supplier, trailing, unamortized, utilized, Vectibix, vi, Vice, vii, viii, xi

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

BIOCQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION

I, Michael W. Nall, hereby certify pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that, to my knowledge, the Quarterly Report on Form 10-Q of Biocept, Inc. for the period ended March 31, 2016 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Biocept, Inc.

Date: May 13, 2016

/s/ Michael W. Nall

Michael W. Nall

President and Chief Executive Officer

(Principal Executive Officer)

This certification accompanies the Report pursuant to Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934.